CTOs on the Move

Pharvaris

www.pharvaris.com

 
Pharvaris is a clinical-stage company focused on bringing oral bradykinin-B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of HAE and other bradykinin-mediated diseases. The company brings together executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE. The company reunites the core team responsible for the discovery and approval of the HAE treatment icatibant. With novel small molecules, we have identified and are advancing potent, orally available compounds targeting this clinically proven therapeutic target.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.pharvaris.com
  • 1 Cranberry Hill Suite 300
    Lexington, MA USA 02421
  • Phone: 212.845.4262

Executives

Name Title Contact Details
Stefan Abele
 Chief Technical Operations Officer Profile

Similar Companies

Critical Outcome Technologies

Critical Outcome Technologies Inc. is a London, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Wheeler Pharmacy

Wheeler Pharmacy is a Lanett, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Greenrise Global Brands

Greenrise is a Canadian publicly traded corporation with its representative office located in Hamburg, Germany and operates in the medical and CBD cannabis markets in Germany.

SpineCenterAtlanta

Visit the orthopedic surgeons and spine specialists at Envision Ortho, serving patients in Atlanta, Augusta, and Savannah, Georgia.

Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Vera`s lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful, including lupus nephritis, a severe renal manifestation of systemic lupus erythematosus.